What are the diagnostic criteria for multisystem atrophy (MSA) in a patient presenting with bradykinesia?

Diagnostic Criteria for Multisystem Atrophy with Bradykinesia

For a patient presenting with bradykinesia, diagnose clinically probable MSA when bradykinesia (poorly levodopa-responsive parkinsonism) is accompanied by cardiovascular or urological autonomic failure, plus supportive MSA red flags and absence of exclusion criteria. 1, 2

Core Clinical Requirements

The 2022 Movement Disorder Society (MDS) criteria establish three clinical diagnostic categories for MSA, all of which can present with bradykinesia 1, 2:

Clinically Established MSA (Highest Specificity)

• Autonomic failure: Cardiovascular (orthostatic hypotension) OR urological dysfunction (urinary incontinence or incomplete bladder emptying) 1, 3
• Poorly levodopa-responsive parkinsonism (which includes bradykinesia as a core feature) OR cerebellar syndrome 1, 2
• Brain MRI markers suggestive of MSA are REQUIRED for this category 1, 2
• Supportive MSA red flags present 1, 3
• No exclusion criteria 1, 3

Clinically Probable MSA (Balanced Sensitivity and Specificity)

• Autonomic failure: Cardiovascular OR urological 1, 2
• Parkinsonism (including bradykinesia and rigidity) OR cerebellar ataxia 1, 2
• Note: Levodopa resistance is NOT required for this category, unlike clinically established MSA 1, 2
• Supportive MSA red flags present 1, 3
• No exclusion criteria 1, 3
• This category showed 95.1% sensitivity and 94.0% specificity in pathological validation studies 2

Clinical Subtypes When Bradykinesia Predominates

MSA-P (Parkinsonian subtype) is diagnosed when extrapyramidal/Parkinsonian features including bradykinesia and rigidity predominate 4. This represents the majority of MSA cases and is also known as striatonigral degeneration 4.

Key Distinguishing Features from Parkinson's Disease

MSA differs from idiopathic Parkinson's disease in several critical ways 4:

• Poor or absent response to levodopa (versus good initial response in PD) 4, 1
• Earlier and more prominent autonomic dysfunction including urinary incontinence 4
• Additional features beyond bradykinesia: cerebellar ataxia, pyramidal signs 4
• Typical age of onset: 55-65 years 4
• Rapid progression: mean disease duration of approximately 6 years 4
• Pathology: synucleinopathy with abnormal cytoplasmic inclusions of ubiquitin and alpha-synuclein in oligodendroglia (versus Lewy bodies in neurons in PD) 4

Supportive MSA Red Flags

Look for these additional features that strengthen the diagnosis 1, 3:

• Motor: Rapidly progressive parkinsonism, early postural instability, early falls, camptocormia, Pisa syndrome, contractures, inspiratory sighs, severe dysphonia/dysarthria, stridor 1, 3
• Non-motor: REM sleep behavior disorder, emotional incontinence 1, 3

Important Clinical Pitfall

A subset of MSA patients (9% in recent autopsy studies) never develop dysautonomia and present with motor symptoms only 5. These patients show significantly longer disease duration (mean 8.1 years versus 6.3 years in those with dysautonomia) 5. The MDS criteria now allow diagnosis based solely on motor symptoms without requiring dysautonomia, expanding the diagnostic scope 5.

Diagnostic Imaging

MRI brain without contrast is the optimal imaging modality for evaluating Parkinsonian syndromes including MSA 4. MRI can demonstrate patterns of regional volume loss characteristic of MSA and is required for the diagnosis of clinically established MSA 1, 2.

Ioflupane SPECT/CT can differentiate Parkinsonian syndromes (including MSA) from essential tremor and drug-induced tremor by demonstrating decreased radiotracer uptake in the striatum, though it cannot distinguish MSA from PD, PSP, or CBD 4.

Prodromal Category

Possible prodromal MSA is a research category designed to capture patients at the earliest disease stages who manifest with autonomic failure or REM sleep behavior disorder plus only mild motor signs including subtle bradykinesia 1, 3.